Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Vogelmeier CF. et al, (2025), Respiratory Medicine, 241, 108015 - 108015
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.
Sciurba FC. et al, (2025), The New England journal of medicine, 392, 1710 - 1720
Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short
Rogliani P. et al, (2025), Expert Review of Respiratory Medicine, 19, 245 - 255
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
Bhatt SP. et al, (2025), The Lancet Respiratory Medicine, 13, 234 - 243
Readability and complexity of written information presented to hospitalised patients for trial consent during the COVID-19 pandemic in the UK: a retrospective document analysis
Gourlay E. et al, (2025), BMJ Open, 15, e089447 - e089447
A response to therapy for COPD with dupilumab
Bhatt SP. et al, (2025), The Lancet Respiratory Medicine, 13, e3 - e3
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Bhatt SP. et al, (2025), Respiratory Medicine, 236, 107846 - 107846
Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial
Hickman K. et al, (2025), Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Ramakrishnan S. et al, (2025), The Lancet Respiratory Medicine, 13, 59 - 68
Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD
Tse G. et al, (2024), Advances in Therapy
Dupilumab for COPD with Elevated Eosinophil Counts
(2024), New England Journal of Medicine, 391, 1163 - 1164
Elevated basophil count is associated with increased odds of endometriosis
Feng Q. et al, (2024), Reproduction and Fertility, 5
QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
Amegadzie JE. et al, (2024), Thorax, 79, 718 - 724
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
Bhatt SP. et al, (2024), New England Journal of Medicine, 390, 2274 - 2283
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19.
Cass SP. et al, (2024), ERJ open research, 10, 919 - 2023
Development and validation of a new algorithm for improved cardiovascular risk prediction
Hippisley-Cox J. et al, (2024), Nature Medicine, 30, 1440 - 1447
Functional MRI assessment of the lungs in fetuses that deliver very Preterm: An MRI pilot study.
Avena-Zampieri CL. et al, (2024), European journal of obstetrics, gynecology, and reproductive biology, 293, 106 - 114
Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S. et al, (2024), The Lancet. Respiratory medicine, 12, 67 - 77
How have we measured trial outcomes of asthma attack treatment? A systematic review.
Howell I. et al, (2024), ERJ open research, 10, 660 - 2023